Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results

Lawrence Cher, Jon Glass, Griffith R. Harsh, Fred H. Hochberg

Research output: Contribution to journalArticlepeer-review

129 Scopus citations

Abstract

Disease-free survival in primary CNS lymphoma has improved with the advent of methotrexate-based pre-irradiation chemotherapy. Prolonged response durations have been noted in six of eight patients refusing radiation therapy in two of our prior series. We have treated an additional 11 patients with methotrexate-based chemotherapy without subsequent planned irradiation. Some received maintenance chemotherapy. Most have had durable responses with little or no toxicity. Prolonged responses can be maintained without radiation therapy, thus avoiding potential long-term radiation toxicity.

Original languageEnglish (US)
Pages (from-to)1757-1759
Number of pages3
JournalNeurology
Volume46
Issue number6
DOIs
StatePublished - Jun 1996
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: Preliminary results'. Together they form a unique fingerprint.

Cite this